3560 results for «370»
3560 results
TAV-in-SAV - Part 1
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the complex world of TAV-in-SAV (Transcatheter Aortic Valve-in-Surgical Aortic Valve) in this comprehensive session. Explore various case studies, including valve-in-valve TAVI in a patient with structural valve deterioration, a successful case of balloon-assisted BASILICA for TAV-in-TAV, and TAVI after valve sparing aortic replacement. Gain...
Lifetime management - First valve choice matters
08 Feb 2025 – From PCR Tokyo Valves 2025
In this expert-led session, explore new frontiers in TAVI, focusing on bicuspid aortic valves, small annulus, and the risk of secondary interventions. Gain insights from the latest randomized trials (RHEIA) and registry data (CAvEAT), with real-world case discussions highlighting their clinical impact.
TAVI complex cases: intravascular hemolysis, Heyde syndrome & more
08 Feb 2025 – From PCR Tokyo Valves 2025
This session presents a diverse array of complex TAVI cases, from interventions for paravalvular leak-induced intravascular hemolysis to cases of severe aortic tortuosity, calcification hindering valve expansion, and successful TAVI in patients with Heyde syndrome and HIV infection. Gain valuable insights into navigating these challenging scenarios.
Management of paravalvular leak
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this comprehensive session on the management of paravalvular leaks, a challenging complication following surgical or transcatheter valve replacements. Discover insights into managing post-operative pulmonary edema, percutaneous closure of left ventricular septal defects, and the nuances of mitigating recurrent paravalvular leaks. Dive into complex cases involving...
Post-procedure complications: leaflet thrombus, hemolytic anemia & more
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this session to discover a range of post-procedure complications that can arise after TAVI, including subacute leaflet thrombus, hemolytic anemia after surgical aortic valve replacement, late migration of papillary fibroelastoma, sinus sequestration, delayed left main occlusion, and high-grade atrioventricular block. Additionally, learn about techniques to...
TAVI and coronary artery disease
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the complex interplay between TAVI and coronary artery disease in this comprehensive session. Explore the decision-making process for optimal sequencing of PCI and TAVI, and examine cases of acute myocardial infarction due to coronary embolism and delayed coronary obstruction following TAVI. Gain insights into...
Redo mitral procedures
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this session to gain insights into the management of recurrent mitral regurgitation after percutaneous mitral valve interventions. Discover various redo procedures, including the use of the PASCAL system for recurrent MR after MitraClip, redo M-TEER for torn posterior leaflet, and successful redo TEER and MitraClip...
High-risk TAVI
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the management of high-risk TAVI cases in this session. Discover innovative approaches, such as Impella-assisted TAVI in severe bicuspid aortic valve disease with severe left ventricular dysfunction, TAVR for pure native aortic regurgitation in surgically unfit patients, and the use of TAVI as a...
TAV-in-TAV cases
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this session to delve into the complexities and challenges of TAV-in-TAV procedures. Gain insights into various case studies, including a successful TAV-in-TAV with coronary protection, a case of CABG and TAV-in-TAV, TAVI in a patient with failed homograft and three previous sternotomies, and concurrent mitral...
The value of WATCHMAN therapy - Who should we treat?
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the value of WATCHMAN therapy in this sponsored session by Boston Scientific. Explore the latest evidence and future perspectives of this innovative treatment option. Understand who the ideal patient is for WATCHMAN therapy and how to identify them in daily clinical practice, including TAVI...
Standardised implant technique with self-expandable valve
08 Feb 2025 – From PCR Tokyo Valves 2025
Don’t miss this PCR Tokyo Valves 2025 session replay, where leading experts share key techniques for simplifying and optimising TAVI procedures with the Evolut device. This session covers essential insights into safely performing procedures on patients with various anatomical types using the self-expandable valve, while emphasising...
Mitral valve-in-valve and valve-in-ring electrosurgery
08 Feb 2025 – From PCR Tokyo Valves 2025
Coronary complications: sharing the unusual ones
23 May 2025 – From EuroPCR 2025
This session shares unusual coronary complications including microcatheter tip entrapment, balloon shaft fracture, coronary balloon rupture salvage, and retained equipment retrieval, highlighting innovative solutions and procedural vigilance.
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
Treatment of a huge femoral artery pseudoaneurysm with a suture based vascular closure device
17 Nov 2020
In this case, a few days after TAVI the heart team has to treat a femoral artery pseudoaneurysm on a 83-year woman. Learn more about their strategy!
Author
Author
Author
PARTNER 3: weighing the comparative costs and savings of TAVI versus SAVR in low-risk patients with severe aortic stenosis
07 Nov 2021
Professor David J. Cohen presented the results of the economic outcomes of the PARTNER 3 trial on Friday, 5 November, in the Late-Breaking Trial session of the Transcatheter Cardiovascular Therapeutics Congress 2021. Giuseppe Biondi-Zoccai provides his analysis of this study.
Author
RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
01 Sep 2024
Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.
The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...
Author
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation
05 Sep 2023
The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...
Author
Author
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
Transfemoral TAVI in the horizontal aorta
12 May 2020
Real-world case report illustrating the benefits of the Portico with FlexNav TAVI system.
